Skip to main content

Casdin Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

95
Companies
$9.0B
Total invested
$114.8M
Avg. check
24
Industries
Biotechnology 21Health Care 12Life Science 11Genetics 6Therapeutics 6Medical 5+18 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 95
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post-IPO Equity
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonVenture - Series Unknown
Scribe Biosciences
June 2023

Flexible tools for single cell analysis

Biotechnology · San FranciscoNon-equity Assistance
4D Molecular Therapeutics
June 2026

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$200.0M Post-IPO Debt
Notch Therapeutics
June 2024

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Biotechnology · Toronto$15.5M Venture - Series Unknown
Genomic Life
May 2024

Genomic Life offers genomic products.

Employee Benefits · La Jolla$10.0M Venture - Series Unknown
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Invetx
May 2022

Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.

Biopharma · Boston$60.5M Series B
Orbital Therapeutics
April 2023

Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.

Alternative Medicine · Cambridge$270.0M Series A
Deepcell
April 2025

Deepcell is a life science company specializing in AI-powered single-cell classification and isolation for basic and translational research.

Artificial Intelligence (AI) · Menlo ParkVenture - Series Unknown
Revolution Medicines
April 2026

Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.

Health Care · Redwood City$1.5B Post-IPO Equity
Function Oncology
April 2023

Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform.

Biotechnology · San Diego$28.0M Series A
Creyon Bio
March 2022

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.

Biotechnology · San Diego$40.0M Series A
Celsius Therapeutics
March 2022

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

Biotechnology · Cambridge$83.0M Series B
Generation Bio
March 2023

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Biotechnology · Cambridge$76.0M Post-IPO Equity
Flare Therapeutics
March 2023

Flare Therapeutics is a biotech startup that creates precision therapies for cancer and other disorders by targeting transcription factors.

Biopharma · Cambridge$123.0M Series B
InnoSIGN
March 2022

InnoSIGN is a manufacturer of precision medicine for diagnostics and drug development applications.

Biotechnology · Eindhoven$8.1M Series A
Basilard BioTech
February 2022

Basilard BioTech features a technology platform that transforms the rapidly growing cell-based therapies market.

Biopharma · CaliforniaSeed
Arzeda
September 2024

Arzeda is a protein design company that creates and manufactures proteins and enzymes for pharmaceuticals and industrial chemicals.

Artificial Intelligence (AI) · Seattle$38.0M Series C
TMRW Life Sciences
July 2024

TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.

Biotechnology · New York$28.2M Series D
iVexSol
January 2023

IVexSol is a lentiviral vector production platform that supplies a consistent source of vectors for successful gene therapy programs.

Manufacturing · Lexington$23.8M Series A
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post Ipo Equity
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post Ipo Equity
Octave
October 2025

Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.

Biotechnology · Menlo ParkGrant

Where Casdin Capital invests

Biotechnology21
Health Care12
Life Science11
Genetics6
Therapeutics6
Medical5

About Casdin Capital's portfolio

How many companies has Casdin Capital invested in?

Casdin Capital has invested in 95 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Casdin Capital invest in?

Casdin Capital's top investment sectors include Biotechnology, Health Care, Life Science, Genetics, Therapeutics. The firm invests across 24 different industry categories.

What is Casdin Capital's largest investment?

Among tracked funding rounds, Revolution Medicines received $1.5B in a Post-IPO Equity round. Casdin Capital's total known invested capital is $9.0B.

What is the average investment size for Casdin Capital?

Casdin Capital's average investment size is $114.8M across its portfolio of 95 companies.

What are Casdin Capital's most recent investments?

Recent Casdin Capital portfolio additions include Prime Medicine, Auron Therapeutics, Scribe Biosciences, 4D Molecular Therapeutics, Notch Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 95 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →